Project description:The IL-6 cytokine Oncostatin M (OSM) is involved in cell development, growth, hematopoiesis, inflammation and cancer. Intriguingly, OSM has proliferative and antiproliferative effects de-pending on the target cell. The molecular mechanisms underlying these opposing effects are not fully understood and its role in tumorigenesis remains controversial. In the present study, we investigated the effect of murine OSM (mOSM) on proliferation in two cell types of distinct origin. We found that mOSM impairs the proliferation of murine bone marrow (BM) stromal cell lines and primary BM stromal cells, whereas murine fibroblasts responded to mOSM with increased proliferation. When we set out to reveal the mechanisms underlying these opposing effects of OSM on proliferation, we detected increased expression of the OSM receptors OSMR and LIFR in stromal cells. Interestingly, Osmr knockdown and Lifr overexpression attenuated the OSM-mediated effect on proliferation in both cell lines indicating that mOSM affected the pro-liferation of both cell lines signaling mainly through the OSMR. Furthermore, mOSM induced activation of the JAK-STAT, PI3K-AKT and MAPK-ERK pathways in OP9 and NIH/3T3 cells with differences in total protein levels between the two cell lines. Our findings offer new insights into the regulation of proliferation by mOSM.
Project description:Analysis of Immediate Early Response 2 (Ier2)-inducible NIH 3T3 cells after Ier2 induction with RheoSwitch ligand RSL-1. Results provide insight into the function of Ier2 in NIH 3T3 mouse embryonal fibroblasts. Immediate early genes, including Ier2, are rapidly induced in quiescent cells by proliferation and migration-inducing stimuli. Microarray gene expression profiling was performed to identify differentially expressed genes following overexpression of Ier2 in NIH 3T3-Ier2 inducible cells after 24 hour induction of Ier2.
Project description:Expression profiling of HepG2 human liver carcinoma cells and NIH 3T3 mouse fibroblasts after arsite treatment for 24h. RNA-seq data comprise 4 groups: NIH 3T3 mouse fibroblasts control and arsite treatment, and HepG2 human liver carcinoma cells control and arsenite treatment. Jena Centre for Systems Biology of Ageing - JenAge (www.jenage.de)
Project description:DUBs exert their biological functions through specific substrates. Theoretically, as a substrate protein of JOSD2, its ubiquitination will be cut by JOSD2. In this regard, an analysis of ubiquitinome assay was performed to identify the potential substrates of JOSD2 in NIH/3T3 cells transfected with Flag-vector or Flag-JOSD2 plasmids.
Project description:The IL-6 family cytokine Oncostatin M (OSM) is involved in cell development, growth, hematopoiesis, inflammation, and cancer. Intriguingly, OSM has proliferative and antiproliferative effects depending on the target cell. The molecular mechanisms underlying these opposing effects are not fully understood. Previously, we found OSM upregulation in different myeloproliferative syndromes. However, OSM receptor (OSMR) expression was detected on stromal cells but not the malignant cells themselves. In the present study, we, therefore, investigated the effect of murine OSM (mOSM) on proliferation in stromal and fibroblast cell lines. We found that mOSM impairs the proliferation of bone marrow (BM) stromal cells, whereas fibroblasts responded to mOSM with increased proliferation. When we set out to reveal the mechanisms underlying these opposing effects, we detected increased expression of the OSM receptors OSMR and LIFR in stromal cells. Interestingly, Osmr knockdown and Lifr overexpression attenuated the OSM-mediated effect on proliferation in both cell lines indicating that mOSM affected the proliferation signaling mainly through the OSMR. Furthermore, mOSM induced activation of the JAK-STAT, PI3K-AKT, and MAPK-ERK pathways in OP9 and NIH/3T3 cells with differences in total protein levels between the two cell lines. Our findings offer new insights into the regulation of proliferation by mOSM.